Introduction
============

A growing body of evidence suggests that during caloric restriction, a low-fat diet (\<30% fat), higher in protein (HP) and lower in carbohydrate, compared with a conventionally recommended high carbohydrate (HC), low-fat diet may offer a number of advantages.^[@bib1]^ These include improving body composition by attenuating the loss of fat-free mass (FFM)^[@bib2],\ [@bib3],\ [@bib4]^ and/or increasing body fat mass (FM) loss^[@bib2],\ [@bib5],\ [@bib6]^ and reducing cardiovascular disease risk factors including insulin sensitivity and the blood lipid profile.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^

Despite this evidence, the majority of studies available that evaluate the role of HP diets as a weight loss strategy have been conducted almost exclusively in female participants.^[@bib3],\ [@bib5],\ [@bib6],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13]^ While the limited number of mixed sex studies have either statistically adjusted for sex and/or were statistically underpowered to evaluate the between-sex differences.^[@bib10],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18]^ Sex differences in protein kinetics have been previously documented;^[@bib19],\ [@bib20]^ hence, whether comparable effects of HP diet previously observed in females are also experienced by males remains largely unknown.^[@bib21]^ This requires urgent investigation as males have a higher proportion of visceral adipose tissue,^[@bib22]^ and a greater risk of cardiometabolic diseases.^[@bib23]^

Therefore, the aim of the current study was to investigate the long-term effects of two, low-fat, hypocaloric diets differing in carbohydrate:protein ratio (HP vs HC), on body composition and cardiometabolic health in overweight and obese males.

Methods
=======

Participants
------------

One hundred and twenty three overweight or obese males were recruited by public advertisement. Participants were excluded if they had a body mass index \<27 or \>40 kg m^−2^, were aged \<20 or \>65 years, had diabetes or uncontrolled hypertension; a history of gastrointestinal, renal, coronary, metabolic or hepatic disease or a malignancy; were taking hypoglycaemic medication or drugs which affect insulin sensitivity, or were smokers. The study was approved by the Human Research Ethics committee of the Commonwealth Scientific and Industrial Research Organisation (CSIRO). Before study inclusion participants were screened at the CSIRO research clinic. All participants provided written informed consent before commencement.

Experimental protocol
---------------------

In a parallel study design, participants were blocked, matched for age and body mass index, then randomised by the trial coordinators using computer-generated random number allocation to consume either an energy-restricted HP, low-fat diet (HP, *n*=59) or an isocaloric high carbohydrate, low-fat diet (HC, *n*=64) for 52 weeks.

At baseline, week 12 and at the end of the intervention (week 52), participants attended the clinic following an overnight fast for outcome assessment. At each assessment visit, participants had height, weight, waist circumference, blood pressure and body composition assessed, before a blood sample was drawn for assessment of blood lipids, creatinine, glucose, insulin and C-reactive protein. For 24 h immediately before the clinical assessments participants conducted a 24-h urine collection for assessment of urinary urea and creatinine. At each outcome assessment clinic visit participants completed a validated physical activity questionnaire.^[@bib24],\ [@bib25]^ Habitual physical activity levels were assessed using the Baecke physical activity questionnaires 'total score\'---an accumulation of the work, sports and non-sports leisure scores derived from the questionnaire. Participants were asked not to modify their lifestyle patterns during the study other than that required to comply with the study protocol. No specific prescription of physical activity was provided. On the basis of the previous studies examining the impact of dietary composition on the primary outcomes of interest,^[@bib4],\ [@bib26]^ it was estimated with an expected dropout of 25% that there would be sufficient power (80%, *P*\<0.05) to detect a minimum difference between the HP and HC diet groups for changes in weight of 1.4 kg, FM of 1.1 kg and FFM of 0.7 kg.

Diets
-----

The dietary patterns were isocaloric and moderate energy restricted (7 MJ per day energy intake). The planned macronutrient profiles of the diets were: HP diet; protein 35% (142 g, ∼1.30 g kg^−1^ per day), carbohydrate 40% (135 g), fat 25% (total 53 g, saturated 14 g). HC diet; protein 17% (88 g, ∼0.85 g kg^−1^ per day), carbohydrate 58% (198 g), fat 25% (total 51 g, saturated 14 g) that was designed to reflect current conventional dietary recommendations.^[@bib27]^ Within the HP diet the prescribed daily protein distribution was approximately 20% (13 g) during the morning, 30% (39 g) at lunch time and 60% (78 g) of protein during the afternoon/evening period.

Participants met individually with a qualified dietician at baseline, and every 2 weeks during the first 12 weeks of the study and monthly thereafter. During these visits participants received detailed dietary prescription, meal planning advice and recipe information. To further facilitate dietary compliance, the dietary patterns were structured into quantities of daily foods and presented as a food checklist ([Table 1](#tbl1){ref-type="table"}). Throughout weeks 0--12, participants were supplied with a 2-week provision of diet-specific key foods, representing approximately 60% of the energy intake, to improve compliance and allow them to familiarise themselves with the food types and quantities utilised in the study. Participants were required to keep daily semi-quantitative food records in which foods consumed with a variable weight were weighed using kitchen scales before recording and foods with a standard unit (i.e., slice of bread) were recorded without pre-weighing. Dietary intake was assessed using a computerised database (Foodworks Professional Edition, version 4, 1998; Xyris Software, Highgate Hill, Australia) based on the analysis of 3 non-consecutive days (1 weekend day and 2 weeks days) of each 2-week period of diet-record data throughout the study. The composite value for dietary intake for weeks 0--12 and 12--52 ([Table 2](#tbl2){ref-type="table"}) was calculated as an average of the 2 week diet-record data blocks within each of the respective periods.

Height, weight, blood pressure and body composition
---------------------------------------------------

Height was measured using a stadiometer (SECA, Hamburg, Germany) and body weight was measured using calibrated electronic digital scales (Mercury; AMZ 14, Tokyo, Japan). Dual-energy X-ray absorptiometry (Lunar Prodigy; General Electric, Madison, WI, USA) was used to measure body composition (total body FM and FFM). Waist circumference was measured on a horizontal plane 2 cm proximal to the uppermost lateral border of the right iliac crest. Seated blood pressure was measured using an automated sphygmomanometer (DYNAMAP 8100, Criticon, Tampa, FL, USA).

Biochemical analysis
--------------------

Serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol), triglycerides, plasma glucose, C-reactive protein and creatinine were measured using commercial enzymatic kits (Roche Diagnostics, Basel, Switzerland) on a Hitachi 902 autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Low-density lipoprotein cholesterol was calculated using a modified Friedewald equation.^[@bib28]^ Insulin was measured using a commercial enzyme immunoassay (Mercodia AB, Uppsala, Sweden). Analysis of 24-h urinary urea and creatinine was performed in a single assay at a commercial laboratory (IMVS, Adelaide, SA, Australia). Creatinine clearance was calculated as (urine creatinine (μmol l^−1^) × urine volume (ml))/(plasma creatinine (μmol l^−1^) × minutes) and corrected for body surface area.^[@bib29]^

Statistical analysis
--------------------

Statistical analyses were performed using SPSS for Windows (version 18.0, SPSS, Chicago, IL, USA). Data were examined for normality before analysis; non-normally distributed variables (triglycerides, C-reactive protein and insulin) were normalised for analysis using logarithmic transformation. Univariate analysis of variance (ANOVA) was used to assess differences in baseline characteristics and dietary data between groups. To evaluate the outcomes of this study, two separate analyses were performed. For the primary analysis (week 52 completers analysis) the effect of time and diet treatment on continuous variables was assessed using repeated measures ANOVA with time as the within subject factor and treatment (HP vs HC) as the between-subject factor. Baseline body mass index was included in the model as a co-variate for body composition outcomes. Where ANOVA showed a statistically significant time by treatment effect, a comparison of the change in each group for each time period (weeks 0--12 and weeks 0--52) was conducted using univariate ANOVA with Bonferroni adjustments for multiple comparisons. For the second analysis, an intention to treat evaluation was conducted using maximal likelihood mixed model analysis with fixed and random effects to analyse expected mean changes over time. The secondary analysis was based on the 120 participants that had outcomes assessed at week 0 and commenced the dietary programme. Between group differences for the proportion of dropouts, participants who lost \>5% and/or 10% of their initial body weight were assessed using *χ*^2^ tests. Pearson\'s correlation coefficients were used to determine relationships between variables. One participant in the HP group was excluded from the dual-energy X-ray absorptiometry body composition analyses because they exceeded the equipment weight limit for scanning at baseline. A blood sample was unable to be obtained from two participants at week 52 (HP 1, HC 1) who were subsequently excluded from the biochemical blood analyses. Five participants (HP 3, HC 2) were excluded from the C-reactive protein results because they had C-reactive protein values\>10 mg l^−1^. Statistical significance was set at *P*\<0.05. Data are reported as means±s.d. unless otherwise specified.

Results
=======

Participants
------------

Three participants withdrew before the commencement of the study (HP 1, HC 2; [Figure 1](#fig1){ref-type="fig"}). One hundred and twenty participants had outcomes assessed at week 0 and commenced the study, 68 participants (57% HP 33, HC 35) completed the intervention and had outcome measurements assessed at week 52. Dropout rates were similar in both groups (HP 25, HC 27; *P*=0.96; [Figure 1](#fig1){ref-type="fig"}). At baseline, outcome variables were similar between completers and non-completers (*P*⩾0.14) except for triglycerides which were higher in the non-completers (2.07±1.01 vs 1.69±0.70 mmol l^−1^, *P*=0.03). Similarly, there were no significant differences between the diet groups at baseline for any outcome variable (*P*⩾0.08, [Table 3](#tbl3){ref-type="table"}) except for triglycerides, which were lower in HP (*P*=0.05). Physical activity levels were similar at baseline (*P*=0.80) and remained relatively constant throughout the intervention in both groups (*P*=0.21 time; *P*=0.07 time × group interaction).

Week 52 completers analysis
---------------------------

### Dietary composition

On the basis of food record data, participants in both groups showed good compliance to the prescribed diets ([Table 2](#tbl2){ref-type="table"}). The diets were similar in total energy (*P*⩾0.05) but participants in the HP diet group consumed less carbohydrate, and more protein and fat than those consuming the HC diet (*P*⩽0.01; [Table 2](#tbl2){ref-type="table"}). Participants achieved relative protein intakes of ∼1.24 and ∼0.82 g kg^−1^ per day in the HP and HC groups, respectively. In both groups overall, week 52 urinary urea correlated with reported protein intake (*r*=0.406, *P*=0.001). Twenty-four-hour urinary urea was significantly higher in the HP group at week 12 (HP 554±216 mmol/24 h vs HC 429±122 mmol/24 h, *P*\<0.01) and week 52 (HP 570±221 mmol/24 h vs HC 460±138 mmol/24 h, *P*=0.02), verifying the higher reported protein intake.

### Body weight and composition

After 52 weeks both groups had similar reductions in body weight ([Table 3](#tbl3){ref-type="table"}), FM and waist circumference (*P*⩽0.01 time; *P*⩾0.11 time × group interaction; [Table 3](#tbl3){ref-type="table"}). Both groups had a similar number of participants who achieved a weight loss of \>5% (HP 85%, HC 83% *P*=0.82) and/or 10% (HP 61%, HC 43% *P*=0.14) of their initial body weight.

Participants who consumed the HP diet lost less FFM (*P*\<0.001 time; *P*\<0.01 time × group interaction; [Table 3](#tbl3){ref-type="table"}). The HP group had a greater reduction in percent body FM at week 12 (*P*\<0.01 time × group interaction; [Table 3](#tbl3){ref-type="table"}). The percentage of weight loss attributed to FFM was HP 21% vs HC 40% at week 12, and HP 21% vs HC 35% at week 52.

### Cardiometabolic risk factors and renal function

After 52 weeks both groups had a similar increase in HDL cholesterol, and reductions in total cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, insulin, blood pressure and C-reactive protein, (*P*\<0.01 time; *P*⩾0.14 time × group interaction; [Table 3](#tbl3){ref-type="table"}). Creatinine clearance did not change in either group during the intervention (*P*=0.18 time; *P*=0.67 time × group interaction; [Table 3](#tbl3){ref-type="table"}). Overall, changes in body weight after 52 weeks correlated with changes in triglycerides (*r*=0.27, *P*=0.03), HDL cholesterol (*r*=−0.41, *P*\<0.01), glucose (*r*=0.49, *P*\<0.001) and insulin (*r*=0.51, *P*\<0.001).

Intention to treat analysis
---------------------------

The secondary maximal likelihood mixed model analysis showed a similar pattern of results to the primary completer\'s analysis ([Table 3](#tbl3){ref-type="table"}). However, for total body FFM and percent total body FM the time × group effect which occurred in the primary completers analysis no longer reached statistical significance (*P*=0.17 and *P*=0.07, respectively; [Table 3](#tbl3){ref-type="table"}).

Overall, the participants who withdrew after week 12 were those who lost less weight during weeks 0--12 than those who completed the full 52 weeks (−7.4±3.0 vs −9.8±4.6 kg; *P*\<0.01). Participants in HP who withdrew after week 12 lost less FM during weeks 0--12 than those participants in HP who completed the full 52 weeks (−5.6±3.3 vs −8.0±3.8 kg; *P*=0.03) and participants in HC who withdrew after week 12 tended to lose less FFM (−2.0±2.5 vs −3.7±4.2 kg; *P*=0.09) compared with the HC participants who completed the 52 weeks.

Discussion
==========

This study showed in overweight and obese men, consuming of a low-fat, energy-restricted diet with a higher protein intake improves body composition to a greater extent compared with an isocaloric HC diet. A HP and HC diet similarly reduced body weight and improved a number of cardiometabolic risk factors.

Overall, both diet groups experienced similar weight loss at 1 year (∼11%); however, the HP diet group lost less FFM such that the FFM percentage contribution to overall weight loss in HP was only just over half that of the HC diet group (21% vs 35%). The mitigation of FFM reduction in HP was anticipated to some degree, given the level of protein intake in HP (∼1.24 g kg^−1^ of body weight vs 0.8 g kg^−1^ body weight in HC) was consistent with protein intakes reported in a meta-analysis by Kreiger *et al.*^[@bib2]^ that were associated with attenuation of FFM loss following hypocaloric-induced weight loss. Leidy *et al.* has reported similar findings in preobese and obese women to those observed in this study, demonstrating during a 12-week hypocaloric weight loss intervention; despite achieving ∼9 kg weight loss across treatment groups, a HP diet (30% protein, 1.4 g kg^−1^per day) mitigated FFM reductions (−1.5 kg loss) compared with an isocaloric HC diet (18% protein, 0.8 g kg^−1^ per day; −2.8 kg). Farnsworth *et al.*^[@bib4]^ also showed that a high-protein, low-fat (HP) diet preserved FFM in hyperinsulinemic females following 12 weeks of energy restriction and 4 weeks of energy balance, but in contrast to the current study, this effect was not evident in their male participants. In the study by Farnsworth *et al.*,^[@bib4]^ females achieved a mean weight loss of 7 kg, FFM was reduced by −0.1 kg in the HP diet group (30% protein, ∼1.24 g kg^−1^ per day during weight loss phase) compared with −1.5 kg in the HC diet group (15% protein, ∼0.68 g kg^−1^ per day). For males, overall weight loss was 10.5 kg, but FFM reduced similarly with both diet treatments (HP diet group −2.5 kg, HC diet group −1.9 kg). However, male participants had higher baseline body weights than their female counterparts and subsequently relative protein intake on the HP diet was markedly less (males: ∼1.02 g kg^−1^ per day vs females: ∼1.23 g kg^−1^ per day). Hence, despite consuming a HP diet, actual protein intake in the males was below that identified in the meta-analysis by Krieger *et al.*^[@bib2]^ as providing a benefit for FFM retention (1.05 g kg^−1^ per day). It is therefore possible that the higher relative protein intake achieved by the male participants in the current study (∼1.24 g kg^−1^ per day) may explain why participants were able to achieve a mitigation of FFM loss in HP compared with HC whereas the male participants in the Farnsworth *et al.*^[@bib4]^ study were not. This suggests that the level of relative protein intake, rather than sex differences in protein metabolism, may be an important underlying determinant in regulating the body composition response to a HP diet.

Despite the differential changes we observed for changes in FFM and percent FM between the diet groups in the completers analysis, it is important to note that significant differences were no longer observed after conducting the secondary mixed model analysis. It is unclear as to why the effects were no longer significant; however, participants who withdrew after week 12 were generally those who lost less weight during weeks 0--12 and may therefore have been those who were less compliant to the diet. Subsequently, the inclusion of these data may have lessened the body composition effects at week 52 in the intention to treat analysis. Alternatively, it is possible the non-random dropout at week 12 relating to body composition (as indicated by the differences in changes in FM in HP and FFM in HC between completers and non-completers) may have biased the completer\'s analysis by favouring a treatment effect.

As FFM is strongly correlated with resting energy expenditure,^[@bib30],\ [@bib31],\ [@bib32]^ accounting for ∼60--70% of daily energy expenditure,^[@bib33]^ the lesser reduction of FFM observed in HP could have implication for achieving sustained weight control following the return to *ad libitum* dietary intake conditions.^[@bib34]^ In addition, as skeletal muscle represents the largest mass of insulin-sensitive tissue,^[@bib35]^ the mitigation of FFM reduction in HP may also provide benefits for metabolic health, particularly in this study population who is at increased risk of developing type 2 diabetes and/or cardiovascular disease.^[@bib36]^ However, there remains a lack of long-term studies investigating the clinical benefits associated with FFM mitigation achieved during weight loss, making it difficult to determine the clinical significance of the changes in FFM observed.

In this study, a statistically significant difference was not observed between the treatment groups for the change in FM in the completers analysis (*P*=0.11) despite a 36% (2.6 kg) greater loss in absolute FM in HP compared with HC at week 52. A number of studies have previously reported a greater reduction in FM with a HP compared with a HC diet.^[@bib5],\ [@bib6]^ The mechanism/s whereby dietary protein may enhance FM reductions are not fully understood. It is plausible that HP diets have a reduced metabolic efficiency, as protein has a reduced energy efficiency for metabolism compared with an equivalent caloric intake of fat or carbohydrate.^[@bib37]^

Marked reductions in cardiometabolic risk factors were observed in both groups. However, no differential changes between the groups were observed. This finding is, in part, consistent with results from the Diet, Obesity, and Genes (DiOGenes) Study, which showed following an initial very low calorie diet-induced weight loss (⩾8%), 26 weeks of consuming one of the 4 *ad libitum* diets varying in either protein:carbohydrate and/or glycemic index had similar effects on the blood lipid profile, blood pressure, fasting insulin and fasting glucose.^[@bib38]^ Conversely, several studies have demonstrated that macronutrient composition of a hypocaloric diet can alter the blood lipid profile response to weight loss.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ Clifton *et al.*^[@bib8]^ conducted a pooled data analysis of three weight loss trials^[@bib4],\ [@bib5],\ [@bib39]^ comparing an energy-restricted HP diet (30--40%, 110--136 g per day) with an isocaloric HC diet (15--20%, 60--67 g day^−1^). Although no differences were observed between dietary patterns for changes in glucose, insulin, total cholesterol, HDL cholesterol or low-density lipoprotein cholesterol, triacylglycerol levels, an independent risk factor for cardiovascular disease,^[@bib40]^ decreased to a greater extent with a HP diet (−0.48 vs −0.27 mmol l^−1^). Although endogenous triglyceride synthesis has been demonstrated to increase in response to a chronic HC diet,^[@bib41]^ a number of potential reasons could explain the lack of any observed between-group effects for triglycerides in the present study. As the HP group had lower triglyceride levels at baseline, participants in this group may not have had the same capacity for improvement compared with those in HC. Alternatively, in this study the absolute reported difference in carbohydrate intake between the groups (∼37 g) may not have been sufficient to induce a differential group effect on plasma triglycerides. It is also possible that the type of carbohydrate prescribed in the HC diet group that was generally from low glycemic index, high-fibre foods ([Table 1](#tbl1){ref-type="table"}) may not have induced the same undesirable effects on plasma triglycerides as contemporary high glycemic index low fat carbohydrate sources.^[@bib41]^ Despite, the absence of any differential group effects, the magnitude of the overall changes in lipids and triglyceride are consistent with the expected per kg change identified in a meta-analysis examining the effect of weight reduction on blood lipids and lipoprotein.^[@bib42]^ These changes represent a substantial reduction in cardiovascular disease risk.^[@bib43]^ C-reactive protein is an inflammatory molecule implicated in the atherosclerotic process and also identified as a predictor of cardiovascular disease.^[@bib44]^ In *ad libitum* conditions, the results of the DiOGenes study showed following weight loss, high-sensitivity C-reactive protein was further reduced when participants consumed a diet with low glycemic index and, to a lesser extent, reduced protein.^[@bib38]^ Although we observed no effect of diet on C-reactive protein in the current study, participants achieved a reduction in C-reactive protein approximately twice that observed during the same duration of intervention with statin therapy.^[@bib45]^

Creatinine clearance was measured as a marker of renal function.^[@bib46]^ Although some concern remains about the impact of higher protein intakes on renal function,^[@bib47]^ no changes in creatinine clearance occurred in either group. However, renal impairment risk to participants in this study was relatively low, given that participants had normal renal function at baseline,^[@bib46]^ and that the reduced energy intake levels would have reduced the absolute quantity of protein ingested on a HP diet to a level equivocal to that consumed on a conventional energy-balanced diet.^[@bib48]^ There is a need for long-term prospective studies to investigate the effect of HP weight loss diets on renal function in patients who have pre-existing renal dysfunction or who are at considerable risk, such as those with type 2 diabetes.^[@bib49]^

This study had several limitations. This study provides a greater understanding of the role of HP and HC weight loss diets in men, but in the absence of a parallel evaluation of women, direct gender comparisons cannot be made and requires additional research. Moreover, while HC diets utilised in previous studies typically delivered relative protein intakes of ∼0.6--0.8 g kg^−1^ per day, considerably wide variability in absolute quantities can occur based on individual body weight, which could be particularly evident between men and women. How absolute vs relative protein intakes may influence the body composition response to weight loss, particularly between genders, remains an area for future research. The relatively high dropout rate (43%) may limit the generalisability of the findings for use in public health treatment programs. However, the attrition rate was comparable to other previous long-term dietary intervention studies^[@bib50],\ [@bib51]^ and the per protocol completers analysis provides a valuable contribution to the literature about the medium to long-term efficacy of a HP weight loss diet for men. There was also some degree of disparity between the protein intakes reported in the food records and the 24-h urinary urea values. Nevertheless, combined these outcomes provide evidence that irrespective of the precise quantity of protein consumed a substantial differential intake was achieved between the diet groups.

In conclusion, in overweight and obese men both a HP and HC diet reduced body weight and improved cardiometabolic risk factors. Consumption of a HP diet was more effective for improving body composition compared with an HC diet.
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###### Food profile of the treatment groups

                                                 *HP*                                                                                         *HC*
  ---------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  Dairy, low fat                                 3 Serves                                                                                     1 Serve
  Lean meat[a](#t1-fn3){ref-type="fn"}           300 g (red meat 4 times weekly)                                                              100 g
  Deli-sliced meat/canned fish                   100 g                                                                                        30 g
  Fresh fruit                                    300 g                                                                                        450 g
  Pasta/rice/potato[a](#t1-fn3){ref-type="fn"}   Nil                                                                                          70 g dry weight
  Bread wholegrain[a](#t1-fn3){ref-type="fn"}    105 g                                                                                        140 g
  Cheese, full fat[a](#t1-fn3){ref-type="fn"}    Nil                                                                                          30 g
  Cereal[a](#t1-fn3){ref-type="fn"}              20 g High fibre[b](#t1-fn4){ref-type="fn"}+2 breakfast biscuits[c](#t1-fn5){ref-type="fn"}   20 g high fibre[b](#t1-fn4){ref-type="fn"}+2 breakfast biscuits[c](#t1-fn5){ref-type="fn"}
  Salad                                          ½ cup                                                                                        ½ cup
  Vegetables                                     ⩾ 2.5 cups                                                                                   ⩾2.5 cups
  Oil/spread                                     20 g                                                                                         20 g
  Wine or equivalent                             750 ml per week                                                                              750 ml per week

Abbreviations: HC, high carbohydrate; HP, high protein.

The treatment groups were a high-protein, low-fat diet (HP) or an isocaloric high carbohydrate, low-fat diet (HC).

Food item provided to participants.

All Bran, Kellogg\'s, Michigan, USA.

Weet-Bix, Sanitarium Health and Wellbeing Company, NSW, Australia.

###### Macronutrient composition of the treatment groups

                                     *HP (*n*=33)*   *HC (*n*=35)*   P*-value*[a](#t2-fn3){ref-type="fn"}
  ---------------------------------- --------------- --------------- --------------------------------------
  *Energy (kJ)*                                                      
   Weeks 0--12                       7134±771        7189±535        0.73
   Weeks 12--52                      7629±1085       7243±739        0.09
                                                                     
  *Protein (g)*                                                      
   Weeks 0--12                       131.1±15.4      82.7±6.7        \<0.001
   Weeks 12--52                      132.4±13.9      83.3±10.3       \<0.001
                                                                     
  *Protein (% of energy)*                                            
   Weeks 0--12                       32.5±3.3        20.5±1.4        \<0.001
   Weeks 12--52                      30.7±3.1        20.4±1.9        \<0.001
                                                                     
  *Carbohydrate (g)*                                                 
   Weeks 0--12                       154.4±31.8      208.4±16.3      \<0.001
   Weeks 12--52                      157.9±28.1      195.2±23.4      \<0.001
                                                                     
  *Carbohydrate (% of energy)*                                       
   Weeks 0--12                       37.4±3.8        51.0±3.6        \<0.001
   Weeks 12--52                      35.9±3.4        47.3±3.9        \<0.001
                                                                     
  *Fat (g)*                                                          
   Weeks 0--12                       50.6±6.5        46.7±7.5        0.30
   Weeks 12--52                      60.0±12.6       52.2±8.7        \<0.01
                                                                     
  *Fat (% of energy)*                                                
   Weeks 0--12                       27.3±3.0        25.0±3.3        \<0.01
   Weeks 12--52                      29.8±3.6        27.7±3.2        0.01
                                                                     
  *Alcohol (g)*                                                      
   Weeks 0--12                       6.5±4.7         8.4±7.2         0.20
   Weeks 12--52                      9.4±8.8         11.2±8.1        0.40
                                                                     
  *Alcohol (% of energy)*                                            
   Weeks 0--12                       2.7±2.0         3.5±2.7         0.21
   Weeks 12--52                      3.6±3.1         4.6±3.2         0.17
                                                                     
  *Saturated fat (g)*                                                
   Weeks 0--12                       15.4±2.2        14.3±2.3        0.06
   Weeks 12--52                      18.4±5.0        16.5±3.5        0.06
                                                                     
  *Saturated fat (% of total fat)*                                   
   Weeks 0--12                       34.3±4.1        34.8±4.8        0.60
   Weeks 12--52                      34.0±4.1        35.3±4.8        0.23

Abbreviations: HC, high carbohydrate; HP, high protein.

Data are means±s.d. The treatment groups were a high-protein, low-fat diet (HP) or an isocaloric high carbohydrate, low-fat diet (HC).

Differences between groups (one way ANOVA).

###### Age, height, body weight and composition, cardiometabolic risk factors and renal function before and after 12 and 52 weeks consumption of either an energy-restricted HP or an isocaloric high carbohydrate, low fat diet (HC)

                                                N                      *HP*         *HC*          P-*value*                      
  --------------------------------------------- ------- -------------- ------------ ------------- ----------- --------- -------- ------
  Age (years)                                   33/35   Week 0         51.3±9.4     50.2±9.3      0.63                            
                                                                                                                                  
  Height (m)                                    33/35   Week 0         1.77±0.06    1.77±0.08     0.71                            
                                                                                                                                  
  Body weight (kg)                              33/35   Week 0         106.0±12.9   101.6±14.9    0.20        \<0.001   0.83     0.92
                                                        Week 12        95.8±11.3    92.2±12.4                                     
                                                        Week 52        93.7±10.7    90.7±12.4                                     
                                                        Change 0--12   −10.2±4.9    −9.4±4.4                                      
                                                        Change 0--52   −12.3±8.0    −10.9±8.6                                     
                                                                                                                                  
  Total body fat mass (kg)                      30/33   Week 0         36.2±7.4     33.6±7.6      0.19        \<0.01    0.11     0.07
                                                        Week 12        28.1±8.6     27.9±8.4                                      
                                                        Week 52        26.2±8.3     26.3±7.9                                      
                                                        Change 0--12   −8.1±3.9     −5.7±4.0                                      
                                                        Change 0--52   −9.9±6.0     −7.3±5.8                                      
                                                                                                                                  
  Total body fat free mass (kg)                 30/33   Week 0         68.3±7.1     68.2±9.9      0.97        \<0.001   \<0.01   0.17
                                                        Week 12        66.1±5.9     64.4±7.3                                      
                                                        Week 52        65.6±5.9     64.3±7.8                                      
                                                        Change 0--12   −2.1±3.7†    --3.8±4.3                                     
                                                        Change 0--52   −2.6±3.7\*   --3.8±4.7                                     
                                                                                                                                  
  Body fat mass (%)                             30/33   Week 0         34.4±5.1     32.9±4.3      0.19        \<0.001   0.02     0.07
                                                        Week 12        29.4±6.9     29.8±5.9                                      
                                                        Week 52        28.2±7.3     28.6±5.6                                      
                                                        Change 0--12   −5.0±3.3†    −3.1±3.7                                      
                                                        Change 0--52   −6.2±4.2     −4.2±4.2                                      
                                                                                                                                  
  Waist circumference (cm)                      32/34   Week 0         111.4±7.8    108.9±10.9    0.30        0.01      0.62     0.24
                                                        Week 12        99.4±7.9     98.3±10.1                                     
                                                        Week 52        98.8±7.4     97.6±9.5                                      
                                                        Change 0--12   −12.0±4.2    −10.5±3.8                                     
                                                        Change 0--52   −12.6±6.4    −11.3±7.0                                     
                                                                                                                                  
  Systolic blood pressure (mm Hg)               31/34   Week 0         133±12       137±13        0.24        \<0.001   0.73     0.78
                                                        Week 12        122±12       124±12                                        
                                                        Week 52        122±12       127±15                                        
                                                        Change 0--12   −11±10       −12±9                                         
                                                        Change 0--52   −10±10       −10±15                                        
                                                                                                                                  
  Diastolic blood pressure (mm Hg)              31/34   Week 0         83±9         85±12         0.55        \<0.001   0.18     0.79
                                                        Week 12        73±7         71±10                                         
                                                        Week 52        74±8         74±8                                          
                                                        Change 0--12   −10±6        −14±8                                         
                                                        Change 0--52   −9±7         −11±11                                        
                                                                                                                                  
  Total cholesterol (mmol l^−1^)                32/34   Week 0         5.11±0.99    5.32±0.78     0.32        \<0.001   0.14     0.46
                                                        Week 12        4.55±0.92    4.45±0.79                                     
                                                        Week 52        4.81±0.89    4.90±0.69                                     
                                                        Change 0--12   −0.55±0.73   --0.88±0.80                                   
                                                        Change 0--52   −0.29±0.52   --0.42±0.64                                   
                                                                                                                                  
  HDL cholesterol (mmol l^−1^)                  32/34   Week 0         1.23±0.36    1.30±0.37     0.44        \<0.001   0.25     0.24
                                                        Week 12        1.26±0.34    1.25±0.33                                     
                                                        Week 52        1.37±0.36    1.37±0.33                                     
                                                        Change 0--12   0.02±0.20    --0.05±0.24                                   
                                                        Change 0--52   0.13±0.17    0.06±0.21                                     
                                                                                                                                  
  LDL cholesterol (mmol l^−1^)                  32/34   Week 0         3.20±0.94    3.19±0.62     0.94        \<0.001   0.34     0.39
                                                        Week 12        2.80±0.85    2.59±0.72                                     
                                                        Week 52        2.94±0.81    2.88±0.63                                     
                                                        Change 0--12   −0.40±0.61   −0.60±0.71                                    
                                                        Change 0--52   −0.27±0.60   −0.31±0.58                                    
                                                                                                                                  
  Triglycerides (mmol l^−1^)                    32/34   Week 0         1.49±0.53    1.85±0.80     \<0.05      \<0.001   0.69     0.36
                                                        Week 12        1.09±0.48    1.36±0.62                                     
                                                        Week 52        1.14±0.78    1.41±0.60                                     
                                                        Change 0--12   −0.40±0.48   −0.49±0.71                                    
                                                        Change 0--52   −0.35±0.74   −0.44±0.59                                    
                                                                                                                                  
  Glucose (mmol l^−1^)                          32/34   Week 0         5.84±0.61    5.77±0.73     0.71        \<0.01    0.66     0.72
                                                        Week 12        5.58±0.43    5.46±0.53                                     
                                                        Week 52        5.63±0.39    5.64±0.76                                     
                                                        Change 0--12   −0.26±0.52   −0.32±0.64                                    
                                                        Change 0--52   −0.21±0.51   −0.13±0.87                                    
                                                                                                                                  
  Insulin (mU l^−1^)                            32/34   Week 0         10.82±8.26   9.29±4.66     0.30        \<0.001   0.49     0.51
                                                        Week 12        6.47±2.80    5.89±2.75                                     
                                                        Week 52        5.41±2.53    7.03±13.29                                    
                                                        Change 0--12   −4.34±6.83   −3.40±3.02                                    
                                                        Change 0--52   −5.41±8.31   −2.26±12.40                                   
                                                                                                                                  
  C-reactive protein (mg l^−1^)                 29/32   Week 0         2.13±1.30    2.43±1.68     0.53        \<0.001   0.75     0.97
                                                        Week 12        2.11±1.61    2.12±1.58                                     
                                                        Week 52        1.58±1.86    1.65±1.35                                     
                                                        Change 0--12   −0.02±1.44   −0.31±1.52                                    
                                                        Change 0--52   −0.55±1.49   −0.78±1.55                                    
                                                                                                                                  
  Creatinine clearance (ml min^−1^1.73 m^−2^)   32/32   Week 0         106.4±24.9   103.1±23.1    0.59        0.18      0.67     0.55
                                                        Week 12        100.7±33.8   97.0±22.8                                     
                                                        Week 52        109.7±39.5   100.6±27.2                                    
                                                        Change 0--12   −5.6±30.2    −6.2±22.1                                     
                                                        Change 0--52   3.3±33.3     −2.5±25.8                                     

Abbreviations: HC, high carbohydrate; HDL, high-density lipoprotein; HP, high protein, low fat; ITT, Intention to Treat; LDL, low-density lipoprotein.

Data are means±s.d.

The treatment groups were a HP or an isocaloric high carbohydrate, low-fat diet (HC).

\**P*\<0.05 Significantly different to HC (univariate ANOVA).

^†^*P*\<0.01 Significantly different to HC (univariate ANOVA).

Comparison of baseline characteristics at week 0 (one way ANOVA).

Changes over time in the groups from weeks 0, 12 and 52 (repeated measures ANOVA).

Treatment effect between groups for the change from weeks 0, 12 and 52 (repeated measures ANOVA).

Treatment effect between groups for the change from weeks 0, 12 and 52 (secondary maximal likelihood mixed model analysis---ITT (*n*=120)).
